Related Experiment Videos
Trial of bivalent influenza A vaccine in high-risk infants
Insights
This study evaluated a bivalent influenza A vaccine in high-risk infants. While generally tolerated, fever reactions were noted, suggesting careful consideration for infants with compensated underlying conditions.
Area of Science:
- Pediatric immunology
- Vaccinology
- Infectious disease prevention
Background:
- Influenza poses a significant risk to high-risk infants.
- Evaluating vaccine safety and immunogenicity in this population is crucial.
- Previous influenza vaccine data in infants is limited.
Purpose of the Study:
- To assess the safety and immunogenicity of a split-virus bivalent influenza A vaccine in high-risk infants.
- To determine antibody responses to specific influenza A components.
- To identify potential adverse reactions in this vulnerable group.
Main Methods:
- A vaccine trial involving 50 high-risk infants aged six to 36 months.
- Administration of a split-virus bivalent influenza A vaccine.
- Monitoring for adverse reactions and measuring hemagglutination-inhibiting antibody titers.
Main Results:
- 18% of infants developed fever (≥100 F), with 7% experiencing higher fevers (≥102 F).
- Antibody response titers were 41% for A/Victoria/75 and 35% for A/New Jersey/8/76.
- Reaction index was higher in high-risk infants compared to older children or normal infants.
Conclusions:
- The bivalent influenza A vaccine, administered in two doses, shows potential effectiveness for infants.
- Infants generally tolerated the vaccine, but fever is a notable adverse reaction.
- Fever development is a concern for infants with marginally compensated underlying diseases.
Abstract:
A vaccine trial involving 50 high-risk infants, aged six to 36 months, was performed for evaluation of the safety of a split-virus bivalent influenza A vaccine. After immunization, 18% of the infants developed a fever of greater than or equal to 100 F and 7% had fever of greater than or equal to 102 F. Other reactions to the vaccine were few. However, the reaction index of these high-risk infants to the bivalent vaccine was higher than those of older children receiving the same vaccine and normal infants receiving the monovalent vaccine. Forty-one percent of the infants responded with a titer of hemagglutination-inhibiting antibody of greater than or equal to 1:20 to the A/Victoria/75 component of the bivalent vaccine, and 35% responded to the A/New Jersey/8/76 component. This result suggested that this vaccine used in two doses would be an effective vaccine for infants. The infants generally tolerated the vaccine well. Nevertheless, the rapid development of fever would be of concern in the infant whose underlying disease was marginally compensated.